Allergy and immunology


Basic research

Cardiovascular medicine

Complementary medicine and alternative therapies

Critical care / intensive care

Dentistry / oral medicine


Emergency medicine




Evidence-based medicine



Geriatric medicine / aging

Haematology / blood transfusion

Health economics

Health policy

History of medicine

Infectious diseases

Internal medicine

Laboratory medicine

Medical education

Medical informatics



Nutrition and metabolism

Obstetrics and gynaecology

Occupational and environmental medicine



Organisation of health care

Otolaryngology / head and neck surgery


Palliative care


Patient-physician relationship

Pharmacology and therapeutics

Primary care, family medicine

Psychiatry and psychotherapy


Public health

Quality of care


Rehabilitation medicine

Renal medicine

Respiratory medicine


Sexual medicine

Sports medicine

Statistics and research methods



Travel medicine


Ops! No article found. Reset filter

Two-dimensional transthoracic echocardiography at rest for the diagnosis, screening and management of pulmonary hypertension

Review article: Biomedical intelligence
Brugger N, Lichtblau M, Maeder M, Muller H, Pellaton C, Yerly P, Swiss Society for Pulmonary Hypertension (SSPH)
Swiss Med Wkly. 2021;151:w20486

This article reviews the current knowledge about methodologic aspects of assessing pulmonary pressure and pulmonary hypertension origin by echo, including a discussion about abnormal thresholds. It also details advanced techniques like right ventricular strain imaging and new concepts like right ventricle – pulmonary artery coupling evaluation that have become “matured” enough to be definitely brought to routine evaluation.

The importance of 18F-FDG cardiac PET/CT for the assessment of myocardial viability in ischaemic heart disease

Caobelli F, Kamani CH, Nkoulou R, Buechel R, Executive Committee of the Swiss Society of Nuclear Medicine (SGNM)
Swiss Med Wkly. 2021;151:w20511

18F-FDG cardiac PET/CT is expected to streamline resource allocation in view of the possibility to avoid costly, invasive procedures and to reduce the rate of future severe complications in coronary artery disease patients, thus further reducing the costs for advanced therapies.

Coronary and structural heart interventions in Switzerland 2019

Original article
Wagener M, Twerenbold R, Cook S, Gämperli O, Meier P, Muller O, Nietlispach F, Räber L, Weilenmann D, Jeger R, on behalf of the Swiss Working Group Interventional Cardiology of the Swiss Society of Cardiology
Swiss Med Wkly. 2021;151:w20495

Since 1987 the Swiss Working Group Interventional Cardiology of the Swiss Society of Cardiology coordinates the assessment of invasive diagnostic and therapeutic heart interventions across Switzerland. In 2019, 37 centres performed a total of 57,975 coronary angiographies. In 48.2% of these cases a subsequent percutaneous coronary intervention was performed. Among a broad spectrum of structural heart interventions, we have observed a constant growth of transcatheter aortic valve implantations, and a total of 1912 transcatheter aortic valve implantations were performed in 2019.

Cost-effectiveness analysis of statins in primary care: results from the Arteris cohort study

Original article
Romanens M, Adams A, Bojara W, Balint S, Warmuth W
Swiss Med Wkly. 2021;151:w20498

The Swiss Federal Office of Public Health performed a health technology assessment regarding statins in primary care. The chosen models may lead to a situation where a clinically indicated statin therapy is estimated not to be cost effective. 

Contemporary early results of late repair of tetralogy of Fallot in children: a single-centre case series

Original article
Mottier V, Prsa M
Swiss Med Wkly. 2021;151:w20491

Compared with the existing literature on complete late repair of tetralogy of Fallot in children, this study showed good early results with no mortality, similar rates of reintervention and valve-preserving surgery, higher ICU and hospital length of stay, higher incidence of significant residual right ventricular outflow tract stenosis, and lower incidence of significant pulmonary insufficiency. Repair with a transannular patch was a risk factor for significant residual right ventricular outflow tract stenosis and significant pulmonary insufficiency.

The SilenT AtRial FIBrillation (STAR-FIB) study programme – design and rationale

Original article
Nozica N, Lam A, Goulouti E, Elchinova E, Spirito A, Branca M, Servatius H, Noti F, Seiler J, Baldinger SH, Haeberlin A, de Marchi SF, Asatryan B, Rodondi N, Donzé J, Aujesky D, Tanner H, Reichlin T, Jüni P, Roten L
Swiss Med Wkly. 2021;151:w20421

Anticoagulation of patients with screen-detected atrial fibrillation may prevent ischaemic strokes. The STAR-FIB study programme aims to determine the age- and sex-specific prevalence of silent atrial fibrillation and to develop a clinical prediction model to identify patients at risk of undiagnosed atrial fibrillation in a hospitalised patient population.

COVID-19 and cardiovascular disease: what have we learned?

Tessitore E, Meyer P
Swiss Med Wkly. 2020;150:w20452

As of 10 December, 82,127 citations were found in PubMed on COVID-19 and 5285 when “COVID-19 and cardiovascular disease” were used as search words. Many cardiovascular societies have also released statements regarding COVID-19. What have we learned from this incredible scientific excitement?

Impact of the COVID-19 pandemic on acute coronary syndromes

Original article
Perrin N, Iglesias JF, Rey F, Benzakour L, Cimci M, Noble S, Degrauwe S, Tessitore E, Mach F, Roffi M
Swiss Med Wkly. 2020;150:w20448

Prolonged delays from symptom onset to first medical contact and a decline in overall ACS incidence were observed during the first wave of the COVID-19 pandemic, with a higher threshold to call for help among ACS patients.

Cardiovascular aspects of COVID-19

Review article: Biomedical intelligence
Kurz DJ, Eberli FR
Swiss Med Wkly. 2020;150:w20417

In this review, findings and debates relating to the diverse aspects of cardiovascular involvement of COVID-19 are summarised and put into perspective. The authors review evidence for the role of the renin-angiotensin-aldosterone system (RAAS), the risk of pre-existing cardiovascular disease in COVID-19 susceptibility and course, and the mechanism of acute and long-term myocardial injury.

The renin-angiotensin-aldosterone system inhibitors in COVID-19: from acidosis to ventilation and immunity

Liao WH, Yang GG, Henneberg M
Swiss Med Wkly. 2020;150:w20444

The authors explain mechanisms by which inhibitors of the renin-angiotensin-aldosterone system may increase susceptibility to and the development of cytokine storm during SARS-CoV-2 infection.

Verpassen Sie keinen Artikel!